Stephen Dilly

    Stephen G Dilly MBBS, PhD
    Chief Executive Officer

    Stephen G. Dilly, MBBS, PhD, is Aimmune’s Chief Executive Officer and a member of Aimmune’s Board of Directors. He was formerly the CEO at APT Pharmaceuticals. Dr. Dilly was previously Senior Vice President, Head of Development, and Chief Medical Officer at Chiron BioPharmaceuticals. Before that, he held a number of senior executive clinical, development and commercial support positions at companies including SmithKline Beecham and Genentech.

    Dr. Dilly played important roles in the development and approval of numerous drugs, including Kytril®, Requip®, Kredex®, Paxil CR®, Cathflo Activase®, Raptiva®, Xolair®, Avastin®, Lucentis®, Cubicin® and Tarceva®. He is on the Board of Sangamo Biosciences. Dr. Dilly received a PhD in Cardiac Physiology from the University of London and holds an MBBS, graduating as a physician from the University of London.

    Howard Raff

      Howard Raff PhD
      Chief Operating Officer

      Howard Raff, PhD, is Aimmune’s Chief Operating Officer. Previously, Dr. Raff was COO at APT Pharmaceuticals and Head of West Coast Operations for The Biologics Consulting Group. He also held executive positions at Chiron Corporation, including Vice President, Development Management, which entailed responsibility for development of the biopharmaceutical portfolio. Dr. Raff spent 11 years in discovery, research and development for Genetic Systems and Bristol-Myers Squibb.

      He has had significant involvement with more than 50 investigational projects, of which several have become marketed pharmaceutical products in the United States and Europe. Early in his career, Dr. Raff was an adjunct associate professor at the University of Washington Medical School. He also served a post-doctoral fellowship for the Howard Hughes Medical Institute at the University of California, San Francisco. Dr. Raff obtained MS and PhD degrees in Immunology and Microbiology from Washington State University.